• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection.

作者信息

Fitzpatrick J M, West A B, Butler M R, Lane V, O'Flynn J D

出版信息

J Urol. 1986 May;135(5):920-2. doi: 10.1016/s0022-5347(17)45923-4.

DOI:10.1016/s0022-5347(17)45923-4
PMID:3959241
Abstract

We treated 414 new patients with stage pTa, grades 1 and 2 bladder tumors by transurethral resection between 1970 and 1982. All of the patients with grade 3 or previous upper tract tumors, or who had been treated at some stage with intravesical chemotherapy were excluded. Followup for 5 or more years was available in 188 of the patients. There was a low increase in T stage (6 per cent). Of the patients followed for 5 or more years 46 per cent remained free of tumor. Only 16 per cent of the patients had multiple tumors at presentation and 20 per cent had tumors of 10 gm. or more. These factors were associated with a worse prognosis. Patients free of tumor at 3 months had an 80 per cent chance of having no further recurrences and this rate remained the same up to 2 years from the start of the disease. Patients with a recurrence at 3 months were much less likely to remain free of tumor, and had a higher chance of recurrence at every future visit.

摘要

相似文献

1
Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection.
J Urol. 1986 May;135(5):920-2. doi: 10.1016/s0022-5347(17)45923-4.
2
Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.浅表性膀胱肿瘤患者的临床全尿路上皮疾病:治疗意义。
J Urol. 2002 May;167(5):2007-11.
3
Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.浅表性膀胱癌经尿道切除术、二次探查切除术及长期化疗预防的回顾性分析:差异化治疗方法的适应证及疗效
J Endourol. 2007 Dec;21(12):1533-41. doi: 10.1089/end.2007.9866.
4
Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.浅表性膀胱癌的预后参数:315例病例分析
J Urol. 1982 Feb;127(2):250-2. doi: 10.1016/s0022-5347(17)53725-8.
5
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.膀胱T1期肿瘤患者接受膀胱内丝裂霉素治疗后重复经尿道切除术对复发率和进展率的影响:一项前瞻性随机临床试验。
J Urol. 2006 May;175(5):1641-4. doi: 10.1016/S0022-5347(05)01002-5.
6
Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.pTa/pT1期膀胱癌患者局部复发的危险因素。
Scand J Urol Nephrol. 2008;42(5):417-21. doi: 10.1080/00365590802016302.
7
Superficial bladder cancer: progression and recurrence.浅表性膀胱癌:进展与复发
J Urol. 1983 Dec;130(6):1083-6. doi: 10.1016/s0022-5347(17)51695-x.
8
The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.p53和bcl-2在浅表性膀胱移行细胞癌中的表达及其在术后膀胱内化疗结局中的作用。
Anticancer Res. 1998 Nov-Dec;18(6B):4717-21.
9
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.浅表性膀胱癌辅助治疗的随机多中心试验:单纯经尿道切除术与经尿道切除术加丝裂霉素C以及经尿道切除术加卡介苗。参与研究的诊所。
J Urol. 1996 Sep;156(3):962-6. doi: 10.1016/s0022-5347(01)65673-8.
10
Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.卡介苗膀胱灌注治疗T1期浅表性膀胱癌
J Urol. 1992 Sep;148(3):797-801. doi: 10.1016/s0022-5347(17)36724-1.

引用本文的文献

1
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.低级别非肌层浸润性膀胱癌:分子图谱、治疗策略及新兴疗法
Nat Rev Urol. 2025 Sep 10. doi: 10.1038/s41585-025-01072-0.
2
Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder.表皮生长因子受体(EGFR)过表达在膀胱尿路上皮癌中的预后意义
BMC Urol. 2018 Jun 7;18(1):59. doi: 10.1186/s12894-018-0373-0.
3
A Multimodal Biomicroscopic System based on High-frequency Acoustic Radiation Force Impulse and Multispectral Imaging Techniques for Tumor Characterization Ex vivo.
基于高频声辐射力脉冲和多光谱成像技术的多模态生物显微镜系统,用于体外肿瘤特征分析。
Sci Rep. 2017 Dec 13;7(1):17518. doi: 10.1038/s41598-017-17367-1.
4
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.加拿大膀胱癌医疗质量改善建议:一份由加拿大膀胱癌协会(BCC)、加拿大泌尿外科肿瘤学组(CUOG)和加拿大泌尿外科协会(CUA)于2015年12月审核并认可的共识文件。
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8.
5
Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence.残留肿瘤微灶和大量调节性T淋巴细胞浸润是膀胱癌复发的原因。
Oncotarget. 2016 Feb 9;7(6):6424-35. doi: 10.18632/oncotarget.7024.
6
CUA guidelines on the management of non-muscle invasive bladder cancer.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南。
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13.
7
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.定义和治疗中间风险非肌肉浸润性膀胱癌谱。
J Urol. 2014 Aug;192(2):305-15. doi: 10.1016/j.juro.2014.02.2573. Epub 2014 Mar 25.
8
Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.丝裂霉素C单次早期灌注与尿液碱化治疗低危非肌层浸润性膀胱癌的初步研究
Drug Des Devel Ther. 2013;7:1-6. doi: 10.2147/DDDT.S39541. Epub 2012 Dec 28.
9
Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.加拿大非肌肉浸润性膀胱癌治疗指南:聚焦膀胱内治疗
Can Urol Assoc J. 2010 Jun;4(3):168-73. doi: 10.5489/cuaj.10051.
10
Update on the management of non-muscle invasive bladder cancer.非肌肉浸润性膀胱癌管理的最新进展
Can Urol Assoc J. 2010 Feb;4(1):56-64. doi: 10.5489/cuaj.777.